Start here
Where are you in your journey?
Choose the path that fits today. We’ll take you to the most useful discussions.
- GLP-1 medication Zepbound, Wegovy, access, side effects, progress, and support.
- Before surgery Compare procedures, plan ahead, and get honest pre-op answers.
- Post-op Recovery, food stages, symptoms, and support.
- Long-term Regain, labs, habits, and life after the honeymoon.
- Revision Explore revision options, complications, and next steps.
Archive, page 2
Clear, source-linked updates on weight-loss surgery and obesity medicines for patients and clinicians.
Patient-first briefs. Linked sources. Evidence without hype.
Older briefs
Page 2
-
Medicare's temporary GLP‑1 Bridge offers eligible Part D members a $50 monthly supply
The Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027 for eligible Part D members.
-
Express Scripts Drops Zepbound's Once-a-Month KwikPen From Its National Formulary
Express Scripts, the pharmacy benefit manager owned by Evernorth, publishes a list of drugs it will not cover for the employers and health plans that use its National Preferred Formulary.
-
Review finds better cardiovascular outcomes after bariatric surgery than drug treatment
A 15-study review compared bariatric surgery with medication in adults who had obesity and type 2 diabetes.
-
AGA's POWER 2.0 brings obesity treatment into routine GI care
The American Gastroenterological Association's updated practice guide asks gastroenterology and hepatology teams to treat obesity with an ongoing, individualized mix of medical and procedural care.
-
ACP names semaglutide and tirzepatide as first-line medication options
A new living guideline conditionally recommends semaglutide or tirzepatide when eligible adults begin medication for weight management alongside lifestyle changes.
-
Phase 3 retatrutide trial reports lower A1C and body weight in type 2 diabetes
In a 40-week placebo-controlled trial, three retatrutide doses lowered A1C and body weight in adults whose type 2 diabetes was not controlled by diet and exercise alone.
-
FDA reports more adverse-event complaints tied to compounded semaglutide and tirzepatide
FDA says it had received 990 reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide by May 31, 2026.
-
UK regulator approves the Wegovy pill for weight loss, a European first
The daily tablet is available only by private prescription for now.
-
VA study finds no one-year rise in overall pancreatitis with GLP‑1 medicines
A large observational study found similar overall one-year pancreatitis rates after patients started a GLP-1 medicine or a sulfonylurea, while an early drug-related signal warrants attention.
-
Ecnoglutide produced more weight loss than semaglutide at 20 weeks in a small China trial
Interim, open-label results from 163 adults favored ecnoglutide at week 20.
-
Phase 3 survodutide trial reports greater weight loss than placebo
In SYNCHRONIZE-1, adults without diabetes lost more weight with weekly survodutide than with placebo at 76 weeks, while gastrointestinal side effects were common.
-
REIMAGINE 1 reports lower A1C and weight with CagriSema than placebo
In 189 adults managing type 2 diabetes with diet and exercise, two CagriSema doses lowered A1C and body weight more than placebo over 40 weeks.
-
REIMAGINE 2 finds a small A1C advantage for CagriSema over semaglutide
In a 68-week phase 3 trial, the higher CagriSema dose lowered A1C 0.16 percentage points more than semaglutide 2.4 mg on average.
-
REIMAGINE 3 tests CagriSema with basal insulin in type 2 diabetes
Adding weekly CagriSema to basal insulin lowered A1C and body weight more than placebo over 40 weeks in a phase 3 trial of 274 adults.
-
Matched health-record study associates bariatric surgery with fewer new atrial arrhythmias
In a matched electronic-health-record analysis, atrial fibrillation or flutter was documented in 2.1% of bariatric surgery patients and 3.3% of nonsurgical controls.
-
ASCO observational analysis links GLP‑1 use with less stage IV progression in four cancers
A propensity-matched database analysis reported lower five-year progression to stage IV disease with GLP-1 medicines than with DPP-4 inhibitors in lung, breast, colorectal, and liver cancer cohorts.
-
Retatrutide reached 28.3% weight loss but remains unapproved
On May 21, 2026, Eli Lilly announced topline Phase 3 results from TRIUMPH-1, the pivotal obesity trial of retatrutide, an investigational once-weekly injection that acts on GLP-1, GIP, and glucagon receptors.
-
Three studies separate weight regain after stopping from two active maintenance strategies
A BMJ meta-analysis estimated regain after weight-management medicines ended, while ATTAIN-MAINTAIN tested a switch to oral orforglipron and SURMOUNT-MAINTAIN tested continued or reduced-dose tirzepatide.
-
Claims study finds GLP‑1 use more than doubled as bariatric surgery use fell
Among 11.7 million insured adults with overweight, obesity, or diabetes diagnoses, GLP-1 use increased 140.4% and bariatric surgery use decreased 34.1% from 2022 through 2024.
-
SURMOUNT-MAINTAIN compares maximum-tolerated, 5 mg, and withdrawn tirzepatide after initial loss
After 60 weeks of open-label tirzepatide, continuing the maximum tolerated dose preserved the largest average weight reduction, 5 mg had an intermediate result, and switching to placebo led to more regain through week 112.
-
Bariatric surgery led incretin drugs in ASMBS comparisons
Meeting abstracts comparing metabolic surgery with incretin drugs report larger one-year weight change and higher remission rates, plus better long-term heart and kidney signals in older adults.
-
Prior GLP‑1 use did not blunt bariatric surgery weight loss
ASMBS-presented Epic Cosmos data show people who took semaglutide or tirzepatide before bypass or sleeve still reached large total losses after the operation.
-
ASMBS meeting data show rising GLP‑1 use, falling operations, and a large treatment gap
One ASMBS meeting analysis found that 90% to 95% of patients whose records showed severe obesity without diabetes received neither treatment studied.
-
Bariatric surgery linked to fewer kidney failures and deaths
A TriNetX comparison of more than 8,900 people with obesity and chronic kidney disease was presented May 5, 2026 in San Antonio.
-
Two-year GLP‑1 claims cost more than sleeve or bypass
Mayo Clinic Florida and Baylor researchers compared matched STATinMED claims in people with obesity and type 2 diabetes.
About this publication
Reporting standards and transparency
How we report
Obesity Treatment News is a BariatricPal publication. We review the linked source material, explain what changed, and state what the evidence does not establish.
Corrections
Send factual corrections through Contact BariatricPal. Material corrections are dated and noted in the article.
Ownership and commerce
BariatricPal owns OTN and the BariatricPal Store. Pages may include clearly separated advertising or store links. Commerce does not change the source summary.
About BariatricPal · Brief author · Contact · Regulation, access, and safety · Clinical practice and outcomes